Innorna Receives Nomination for the Prestigious Prix Galien USA Best Startup Award in 2026

Innorna Nominated for the 2026 Prix Galien USA Best Startup Award

In a remarkable achievement, Innorna, a clinical-stage biotech company pioneering RNA medicines, has been nominated for the prestigious 2026 Prix Galien USA Best Startup Award. This nomination highlights Innorna's innovation in the mRNA-LNP platform and its clinical pipeline that has transcended beyond vaccines into therapeutic applications.

The core of Innorna's research is exemplified by its lead program, IN026, which represents a cutting-edge mRNA therapy aimed at treating refractory gout by targeting uric acid levels. Notably, Innorna secured FDA IND clearance for this program in March 2026, marking a significant milestone in extending the use of mRNA technology to address chronic diseases.

Recognized as the Nobel Prize equivalent within the biopharmaceutical industry, the Prix Galien honors exceptional achievements in medical innovation that substantially enhance human health. The winners are selected by committees composed of leading biomedical scientists, high-profile industry executives, and Nobel Laureates from various corners of the globe.

Dr. Linxian Li, the Founder and CEO of Innorna, expressed his gratitude, stating, "We are honored to be named a Prix Galien USA Best Startup nominee. This recognition affirms the strides our team has made in advancing our clinical pipeline, which is built on an extensive foundation of dedicated platform engineering. It serves as a driving force behind our mission to develop RNA medicines that can provide improved options for patients and enrich lives around the world."

The winners of the 2026 Prix Galien USA Awards will be disclosed at a ceremony scheduled for October 29, 2026, hosted at the American Museum of Natural History in New York City.

About Innorna

Innorna is at the forefront of RNA medicine innovation, focusing on enhancing lives through continuous development in both platform and pipeline technologies. The company is substantially supported by a growing intellectual property portfolio and has formulated a proprietary RNA delivery system, which encompasses a strategically designed library exceeding 6,000 diverse ionizable lipids as well as targeted LNP delivery systems and advanced mRNA technologies. With integrated capabilities spanning from discovery to cGMP manufacturing, Innorna showcases deep technological expertise and accelerates development to maintain high capital efficiency.

The company is advancing an expanding pipeline of mRNA therapies targeting chronic diseases, in vivo immunotherapies, and vaccines, having successfully raised $150 million to date. Innorna's commitment to push the boundaries of RNA therapeutics positions it as a trailblazer in this ever-evolving domain of medicine.

The recognition and nomination at the Prix Galien are not just accolades, but serve as a strong testament to Innorna's dedication towards innovation in improving health outcomes on a global scale. As the biopharmaceutical industry continues to evolve, Innorna stands ready to lead with transformative solutions through its groundbreaking research and development efforts.